Jefferies Financial Group Boosts DexCom (NASDAQ:DXCM) Price Target to $200.00

DexCom (NASDAQ:DXCM) had its price target raised by Jefferies Financial Group from $180.00 to $200.00 in a report issued on Thursday, The Fly reports. The firm presently has a “buy” rating on the medical device company’s stock. Jefferies Financial Group’s price target would suggest a potential upside of 0.97% from the stock’s current price. Jefferies Financial Group also issued estimates for DexCom’s Q1 2020 earnings at $0.15 EPS, Q2 2020 earnings at $0.28 EPS, Q3 2020 earnings at $0.45 EPS and Q4 2020 earnings at $0.67 EPS.

Other equities research analysts have also recently issued reports about the company. Raymond James increased their price objective on DexCom from $150.00 to $172.00 and gave the company an “outperform” rating in a research report on Thursday, August 1st. Canaccord Genuity increased their price objective on DexCom from $160.00 to $185.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. Robert W. Baird increased their price objective on DexCom from $186.00 to $195.00 and gave the company an “outperform” rating in a research report on Thursday, August 29th. Zacks Investment Research raised DexCom from a “hold” rating to a “buy” rating and set a $154.00 price objective on the stock in a research report on Friday, October 25th. Finally, BidaskClub raised DexCom from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. Five equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. DexCom presently has an average rating of “Buy” and a consensus price target of $190.67.

Shares of DexCom stock traded up $3.38 during midday trading on Thursday, reaching $198.08. 2,580,200 shares of the company’s stock traded hands, compared to its average volume of 1,138,483. DexCom has a 12 month low of $105.05 and a 12 month high of $200.80. The company has a market cap of $14.00 billion, a PE ratio of 660.27 and a beta of 0.64. The stock has a 50 day moving average of $155.57 and a 200-day moving average of $146.29. The company has a debt-to-equity ratio of 1.56, a quick ratio of 5.64 and a current ratio of 6.05.

DexCom (NASDAQ:DXCM) last released its earnings results on Wednesday, November 6th. The medical device company reported $0.65 EPS for the quarter, topping analysts’ consensus estimates of $0.20 by $0.45. DexCom had a positive return on equity of 10.41% and a negative net margin of 13.96%. The firm had revenue of $396.30 million for the quarter, compared to analysts’ expectations of $348.99 million. During the same period in the prior year, the firm posted $0.17 earnings per share. The company’s quarterly revenue was up 48.6% on a year-over-year basis. On average, equities analysts anticipate that DexCom will post 0.94 earnings per share for the current fiscal year.

In other DexCom news, SVP Heather S. Ace sold 7,243 shares of the stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $174.80, for a total value of $1,266,076.40. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Kevin R. Sayer sold 14,322 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $149.86, for a total value of $2,146,294.92. The disclosure for this sale can be found here. Insiders have sold 105,222 shares of company stock worth $16,407,406 over the last ninety days. 1.80% of the stock is currently owned by insiders.

A number of hedge funds have recently bought and sold shares of the business. Cambridge Investment Research Advisors Inc. lifted its holdings in DexCom by 1.5% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 4,643 shares of the medical device company’s stock valued at $696,000 after acquiring an additional 67 shares during the period. World Asset Management Inc lifted its holdings in DexCom by 2.4% in the second quarter. World Asset Management Inc now owns 2,982 shares of the medical device company’s stock valued at $447,000 after acquiring an additional 69 shares during the period. Steward Partners Investment Advisory LLC lifted its holdings in DexCom by 33.3% in the third quarter. Steward Partners Investment Advisory LLC now owns 280 shares of the medical device company’s stock valued at $41,000 after acquiring an additional 70 shares during the period. SeaCrest Wealth Management LLC lifted its holdings in DexCom by 5.4% in the third quarter. SeaCrest Wealth Management LLC now owns 1,413 shares of the medical device company’s stock valued at $211,000 after acquiring an additional 73 shares during the period. Finally, First Republic Investment Management Inc. lifted its holdings in DexCom by 3.3% in the second quarter. First Republic Investment Management Inc. now owns 3,093 shares of the medical device company’s stock valued at $463,000 after acquiring an additional 100 shares during the period. 96.19% of the stock is currently owned by institutional investors.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Recommended Story: Return on Equity (ROE)

The Fly

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.